Clinical and Epidemiological Characteristics of the 2022 Mpox Outbreak in Spain (CEME-22 Study)
© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America..
Background: We conducted a multicentric national study (SEIMC-CEME-22), to describe the clinical and epidemiological profile of the mpox outbreak in Spain, including the management of the disease.
Methods: This was a retrospective national observational study conducted by Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC) and Foundation SEIMC-GESIDA. We included patients with a confirmed mpox diagnosis before 13 July 2022, and attended at the Spanish health network (the early phase of the outbreak). Epidemiological, clinical, and therapeutic data were collected.
Results: Of a total of 1472 patients from 52 centers included, 99% of them were cisgender men, mostly middle-aged, and 98.6% were residents in Spain. The main suspected route of transmission was sexual exposure, primarily among MSM. Occupational exposure was reported in 6 patients. Immunosuppression was present in 40% of patients, mainly due to human immunodeficiency virus (HIV). Only 6.5% of patients had been vaccinated against orthopoxvirus. Virus sequencing was performed in 147 patients (all B.1 lineage). Rash was the most frequent symptom (95.7%), followed by fever (48.2%), adenopathies (44.4%) myalgias (20.7%), proctitis (17%), and headache (14.7%). Simultaneously diagnosed sexually transmitted infections included syphilis (n = 129), gonococcal infection (n = 91), HIV (n = 67), chlamydia (n = 56), hepatitis B (n = 14), and hepatitis C (n = 11). No therapy was used in 479 patients (33%). Symptomatic therapies and antibiotics were used in 50% of cases. The most used therapy regimens were systemic corticoids (90 patients), tecovirimat (6 patients), and cidofovir (13 patients). Smallpox immunoglobulins were used in 1 patient. Fifty-eight patients were hospitalized, and 1 patient died.
Conclusions: Mpox outbreak in Spain affected primarily middle-aged men who were sexually active and showed a high rate of HIV infection. A range of heterogeneous therapeutics options was performed.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Open forum infectious diseases - 11(2024), 3 vom: 08. März, Seite ofae105 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ramírez-Olivencia, G [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 26.03.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1093/ofid/ofae105 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370137892 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370137892 | ||
| 003 | DE-627 | ||
| 005 | 20240327000144.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240325s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/ofid/ofae105 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1349.xml |
| 035 | |a (DE-627)NLM370137892 | ||
| 035 | |a (NLM)38524223 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ramírez-Olivencia, G |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical and Epidemiological Characteristics of the 2022 Mpox Outbreak in Spain (CEME-22 Study) |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 26.03.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America. | ||
| 520 | |a Background: We conducted a multicentric national study (SEIMC-CEME-22), to describe the clinical and epidemiological profile of the mpox outbreak in Spain, including the management of the disease | ||
| 520 | |a Methods: This was a retrospective national observational study conducted by Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC) and Foundation SEIMC-GESIDA. We included patients with a confirmed mpox diagnosis before 13 July 2022, and attended at the Spanish health network (the early phase of the outbreak). Epidemiological, clinical, and therapeutic data were collected | ||
| 520 | |a Results: Of a total of 1472 patients from 52 centers included, 99% of them were cisgender men, mostly middle-aged, and 98.6% were residents in Spain. The main suspected route of transmission was sexual exposure, primarily among MSM. Occupational exposure was reported in 6 patients. Immunosuppression was present in 40% of patients, mainly due to human immunodeficiency virus (HIV). Only 6.5% of patients had been vaccinated against orthopoxvirus. Virus sequencing was performed in 147 patients (all B.1 lineage). Rash was the most frequent symptom (95.7%), followed by fever (48.2%), adenopathies (44.4%) myalgias (20.7%), proctitis (17%), and headache (14.7%). Simultaneously diagnosed sexually transmitted infections included syphilis (n = 129), gonococcal infection (n = 91), HIV (n = 67), chlamydia (n = 56), hepatitis B (n = 14), and hepatitis C (n = 11). No therapy was used in 479 patients (33%). Symptomatic therapies and antibiotics were used in 50% of cases. The most used therapy regimens were systemic corticoids (90 patients), tecovirimat (6 patients), and cidofovir (13 patients). Smallpox immunoglobulins were used in 1 patient. Fifty-eight patients were hospitalized, and 1 patient died | ||
| 520 | |a Conclusions: Mpox outbreak in Spain affected primarily middle-aged men who were sexually active and showed a high rate of HIV infection. A range of heterogeneous therapeutics options was performed | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a HIV | |
| 650 | 4 | |a STI | |
| 650 | 4 | |a emerging infections | |
| 650 | 4 | |a mpox | |
| 650 | 4 | |a tecovirimat | |
| 700 | 1 | |a Velasco Arribas, M |e verfasserin |4 aut | |
| 700 | 1 | |a Vera García, M M |e verfasserin |4 aut | |
| 700 | 1 | |a Casabona, J |e verfasserin |4 aut | |
| 700 | 1 | |a Martínez, M J |e verfasserin |4 aut | |
| 700 | 1 | |a Membrillo De Novales, F J |e verfasserin |4 aut | |
| 700 | 0 | |a CEME-22 Study Group |e verfasserin |4 aut | |
| 700 | 1 | |a Ramírez-Olivencia, G |e investigator |4 oth | |
| 700 | 1 | |a Arribas, M Velasco |e investigator |4 oth | |
| 700 | 1 | |a García, M M Vera |e investigator |4 oth | |
| 700 | 1 | |a Casabona, J |e investigator |4 oth | |
| 700 | 1 | |a Martínez, M M |e investigator |4 oth | |
| 700 | 1 | |a De Novales, F J Membrillo |e investigator |4 oth | |
| 700 | 1 | |a García, E Orviz |e investigator |4 oth | |
| 700 | 1 | |a Ubeda, A Cabello |e investigator |4 oth | |
| 700 | 1 | |a Muñoz, P |e investigator |4 oth | |
| 700 | 1 | |a López, P Álvarez |e investigator |4 oth | |
| 700 | 1 | |a De La Serna, J I Bernardino |e investigator |4 oth | |
| 700 | 1 | |a Camacho, I Pérez |e investigator |4 oth | |
| 700 | 1 | |a González, J López-Contreras |e investigator |4 oth | |
| 700 | 1 | |a Liarte, Á Gutiérrez |e investigator |4 oth | |
| 700 | 1 | |a Ryan, P |e investigator |4 oth | |
| 700 | 1 | |a Guerra, G Jiménez |e investigator |4 oth | |
| 700 | 1 | |a Gallego, M J Vivancos |e investigator |4 oth | |
| 700 | 1 | |a Gutiérrez, M J Urrutikoetxea |e investigator |4 oth | |
| 700 | 1 | |a Betancor, M A Hernández |e investigator |4 oth | |
| 700 | 1 | |a Beamonte, A M Milagro |e investigator |4 oth | |
| 700 | 1 | |a González, E Lagaretos |e investigator |4 oth | |
| 700 | 1 | |a Serrano, A Muñoz |e investigator |4 oth | |
| 700 | 1 | |a Jiménez, J A Lepe |e investigator |4 oth | |
| 700 | 1 | |a Sancho, A Ruiz |e investigator |4 oth | |
| 700 | 1 | |a Flórez, J Alcoba |e investigator |4 oth | |
| 700 | 1 | |a De Cea, Á Mena |e investigator |4 oth | |
| 700 | 1 | |a Lorite, M N Navarrete |e investigator |4 oth | |
| 700 | 1 | |a Corma-Gómez, A |e investigator |4 oth | |
| 700 | 1 | |a Ocete, M D |e investigator |4 oth | |
| 700 | 1 | |a Sacristán, M Simón |e investigator |4 oth | |
| 700 | 1 | |a Segarra, O Martín |e investigator |4 oth | |
| 700 | 1 | |a Román, A Rivero |e investigator |4 oth | |
| 700 | 1 | |a Sánchez, E Delgado |e investigator |4 oth | |
| 700 | 1 | |a Tendero, D Torrús |e investigator |4 oth | |
| 700 | 1 | |a Borrego, B Valle |e investigator |4 oth | |
| 700 | 1 | |a Gámez, S L Sanbonmatsu |e investigator |4 oth | |
| 700 | 1 | |a Van Den Eynde, E |e investigator |4 oth | |
| 700 | 1 | |a González, A Pérez |e investigator |4 oth | |
| 700 | 1 | |a Serra, F Artigues |e investigator |4 oth | |
| 700 | 1 | |a Pérez, P González-Ruano |e investigator |4 oth | |
| 700 | 1 | |a Neira, D V Gerez |e investigator |4 oth | |
| 700 | 1 | |a Amador-Prous, C |e investigator |4 oth | |
| 700 | 1 | |a Galparsoro, H Azkune |e investigator |4 oth | |
| 700 | 1 | |a Martín, L Mao |e investigator |4 oth | |
| 700 | 1 | |a Rosado, D García |e investigator |4 oth | |
| 700 | 1 | |a Expósito, Ó Martínez |e investigator |4 oth | |
| 700 | 1 | |a Fernández-Llamazares, G Soria |e investigator |4 oth | |
| 700 | 1 | |a Soto, M Blanco |e investigator |4 oth | |
| 700 | 1 | |a Rodríguez, M Á Morán |e investigator |4 oth | |
| 700 | 1 | |a Castellano, M M Treviño |e investigator |4 oth | |
| 700 | 1 | |a Masiá, M M |e investigator |4 oth | |
| 700 | 1 | |a Navarro, A M Castillo |e investigator |4 oth | |
| 700 | 1 | |a Berrocal, M A Sepúlveda |e investigator |4 oth | |
| 700 | 1 | |a Gómez, L Sánchez |e investigator |4 oth | |
| 700 | 1 | |a Alonso, A Vallejo |e investigator |4 oth | |
| 700 | 1 | |a Artero, E Álvarez |e investigator |4 oth | |
| 700 | 1 | |a Barberá, M D C Sáez |e investigator |4 oth | |
| 700 | 1 | |a Morell, E Bernal |e investigator |4 oth | |
| 700 | 1 | |a Ayerdi, Ó |e investigator |4 oth | |
| 700 | 1 | |a Acosta, I Carrillo |e investigator |4 oth | |
| 700 | 1 | |a Veintimilla, C |e investigator |4 oth | |
| 700 | 1 | |a Vidovic-Mendoza, P |e investigator |4 oth | |
| 700 | 1 | |a Mora, M |e investigator |4 oth | |
| 700 | 1 | |a Baza, B |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Open forum infectious diseases |d 2014 |g 11(2024), 3 vom: 08. März, Seite ofae105 |w (DE-627)NLM243576811 |x 2328-8957 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2024 |g number:3 |g day:08 |g month:03 |g pages:ofae105 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/ofid/ofae105 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2024 |e 3 |b 08 |c 03 |h ofae105 | ||